Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae said it plans to fund its ongoing operations using its cash on hand. According to its most recent financial report, the company had about $168 million in cash, cash equivalents and restricted ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min More than 4 million people have ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

As of the third quarter of 2023, Invitae had already tallied a net loss of more than $1.3 billion for the year, with cash burn of $311 million as of Sept. 30 and just under $265 million left in cash ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. San Francisco genetic testing firm Invitae succeeded this ...

SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical ...

First, a bit of background on this genetic testing expert. The company sells a wide variety of genetic tests that inform you of your risk for genetic disease or of passing a particular condition on if ...